Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients


Bronchial asthma is a common respiratory disease characterized by chronic airway inflammation, which have been affecting about 1-18% of the population in the world, causing tremendous economic burden for the patients and countries. Generally, asthma is a heterogeneous disease, and it could be classified into many types on the basis of symptoms, that is, typical asthma, cough variant asthma, and chest tightness variant asthma etc. Typical asthma (TA) is defined according to the history of repeated respiratory symptoms such as wheeze, shortness of breath, chest tightness, and cough, usually with reversible airflow limitation, airway hyper-responsiveness, and airway remodeling. Cough variant asthma (CVA) is characterized by the single manifestation, recurrent cough, which could be improved after the use of bronchodilators. However, according to different guidelines, it is still controversial on the treatment of CVA and TA. The guidelines of Global Initiative for Asthma(GINA) in 2014 put forward the treatment of TA patients, but did not list the treatment specific to CVA. The guideline of ACCP(American College of Chest Physicians) and cough guidelines of China are proposed to treat the CVA effectively with bronchial diastolic drug. Inhaled corticosteroids (ICS) and leukotriene receptor antagonists are effective for the treatment of CVA. Currently, more and more studies supported that application of ICS combined with bronchial dilation agents is more beneficial to CVA patients. Budesonide/formoterol is a compound of ICS and long-acting beta2-agonist(LABA), which can not only be used as a maintenance medication, but also be used as a relief medication, namely, budesonide/formoterol treatment regimen for SMART (Symbicort as both maintenance and reliever therapy). Most studies show that SMART treatment can be used in the treatment of TA patients. But the study on whether budesonide/formoterol can be used to treat CVA is still little. To provide basis for clinical medication guidance for patients with CVA and TA, this study will enroll 30 patients with TA or CVA , who will be required to adopt the SMART regimen in the following 6 months.The symptom score, airway inflammation, pulmonary function and airway reactivity changes, will be measured every mouth. After the study finished, the investigators will compare the difference between the two groups.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: January 2017


  • Drug: budesonide 160μg/formoterol 4.5μg
    • SMART regimen

Arms, Groups and Cohorts

  • Other: patients with CVA(CVA group)
    • budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months
  • Other: patients with TA(TA group)
    • budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for six months

Clinical Trial Outcome Measures

Primary Measures

  • Forced Expiratory Volume in first second
    • Time Frame: up to six months

Secondary Measures

  • forced vital capacity
    • Time Frame: up to six months
  • Fractional Exhaled Nitric Oxide
    • Time Frame: up to six months
  • Asthma Controlled Test
    • Time Frame: up to six months
  • Bronchial Provocation Test
    • Time Frame: up to six months

Participating in This Clinical Trial

Inclusion Criteria

1. aged 15-75 2. first diagnosed corresponding to the diagnostic standards established by Asthma Committee, Respiratory Society, Chinese Medical Association, or previously diagnosed asthma without regular treatment 3. Mch bronchial provocation test is positive 4. the chest X-ray is normal. Exclusion Criteria:

1. accompanied by other disease of respiratory system 2. combined with serious illness of other system, such as myocardial infarction, severe arrhythmia, malignant tumors and so on 3. women with pregnancy or lactation.

Gender Eligibility: All

Minimum Age: 15 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Zhujiang Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Huapeng Yu, Ph.D, Study Director, Southern Medical University, China
  • Overall Contact(s)
    • Shuyu Chen, M.D, +8613580421202,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.